Showing 7471-7480 of 8649 results for "".
- Oyster Point Pharma Names Donald Santel as Chairman of the Board of Directorshttps://modernod.com/news/oyster-point-pharma-names-donald-santel-as-chairman-of-the-board-of-directors/2479427/Oyster Point Pharma announced the appointment of Donald Santel as non-executive Chairperson and a Director of the company and a member of the Compensation Committee. Mr. Santel joined the Board on July 30, 2021, and will take over as Chairperson as Ali Behbahani, MD, steps down as Ch
- Study Shows Reduction in Postoperative Halos in Patients Treated With Tearscience Lipiflow Treatment Prior to Bilaterial Cataract Surgeryhttps://modernod.com/news/study-shows-reduction-in-postoperative-halosin-patients-treated-with-tearscience-lipiflow-treatment-prior-to-bilaterial-cataract-surgery/2479413/Johnson & Johnson Vision revealed new comparative clinical study findings evaluating TearScience LipiFlow treatment in cataract surgery. The data concluded that treating patients with TearScience LipiFlow prior to cataract surgery significantly reduced patient-reports of halos compared to con
- United Nations Resolution Designed to Tackle Preventable Sight Losshttps://modernod.com/news/united-nations-resolution-designed-to-tackle-preventable-sight-loss/2479406/The United Nations General Assembly (UNGA) has adopted
- Scientists Discover Gene Therapy Provides Neuroprotection to Prevent Glaucoma Vision Losshttps://modernod.com/news/scientists-discover-gene-therapy-provides-neuroprotection-to-prevent-glaucoma-vision-loss/2479407/A form of gene therapy protects optic nerve cells and preserves vision in mouse models of glaucoma, according to research supported by NIH’s National Eye Institute. The findings suggest a way forward for developing neuroprotective therapies for glaucoma, a leading cause of visual impairment and b
- EyePoint Pharmaceuticals Receives Preliminary Extension to Pass-Through Payment Status for Dexycuhttps://modernod.com/news/eyepoint-pharmaceuticals-receives-preliminary-extension-to-pass-through-payment-status-for-dexycu/2479385/EyePoint Pharmaceuticals announced today that the company expects to receive a 9-month extension on Dexycu’s pass-through payment status, which otherwise would expire on March 31, 2022. On July 19, 2021, CMS released its 2022 draft Hospital Outpatient Prospective
- Harrow Health Granted Two Patents for Novel Surgical Dilation Formulationhttps://modernod.com/news/harrow-health-granted-two-patents-for-novel-surgical-dilation-formulation/2479377/Harrow Health announced that the United States Patent and Trademark Office issued two patents, entitled “Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof.” Harrow Health’s wholly owned subsidiary, ImprimisRx, provides surgical dilation (
- Heru Bolsters Executive Team with Seasoned Industry Veteranshttps://modernod.com/news/heru-bolsters-executive-team-with-seasoned-industry-veterans/2479373/Heru, a developer of wearable AI-powered vision diagnostics and augmentation software, has expanded its executive leadership team with the appointment of several strategic hires. Joining Heru are Mary Durbin, PhD, as Chief Scientific Officer; Bob George as Chief Technology Officer; Corey Nielson
- Hoya Vision Care and Myopia Profile Training the Visionaries of the Futurehttps://modernod.com/news/hoya-vision-care-and-myopia-profile-training-the-visionaries-of-the-future/2479370/Hoya Vision Care announced the roll out of a suite of co-created certified training courses to educate, inform and empower eye care professionals (ECPs) to prescribe spectacle lenses for children in the global fight t
- First-Of-Its-Kind Visual Prosthesis Brain Implant Developed in Chicago Moves to Clinical Trialhttps://modernod.com/news/first-of-its-kind-visual-prosthesis-brain-implant-developed-in-chicago-moves-to-clinical-trial/2479367/The Intracortical Visual Prosthesis (ICVP) is an implant that connects directly to the brain’s visual cortex, bypassing the retina and optic nerves. The National Institutes of Health has awarded Illinois Tech researchers $2.5 million for the first year of a 3-year project that includes implanting
- CATS Tonometer Receives FDA Clearance for Disposable Tonometer Prismhttps://modernod.com/news/cats-tonometer-receives-fda-clearance-for-disposable-tonometer-prism/2479364/The CATS-D Disposable Prism, designed to deliver improved IOP measurement accuracy using a sterile, disposable tip replacement for the Goldmann Tonometer, received FDA clearance and will be available for sale in the fall of 2021. “The CATS Tonometer Prism is designed to provide more accura